Can a targeted antibody slow advanced pancreatic cancer?

NCT ID NCT05141149

Ongoing Disease control Sponsor: Prestige Biopharma Limited Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests an experimental antibody, PBP1510, designed to block a protein called PAUF that may help pancreatic cancer grow. The study includes two parts: first, finding a safe dose of PBP1510 alone or with the chemotherapy gemcitabine; second, testing the best dose in a larger group. Participants are adults with advanced or metastatic pancreatic cancer whose disease has worsened after prior treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental antibody called PBP1510, given alone or with the chemotherapy drug gemcitabine
What this could lead to: If successful, this could point toward a new treatment option for advanced pancreatic cancer.
What could go wrong: This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. Side effects may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Hospital Universitario La Paz

Madrid, Madrid, 28046, Spain
Monash Health

Melbourne, Australia
National Cancer Centre Singapore

Singapore, Singapore
Northwell Health / R.J. Zuckerberg Cancer Center

New Hyde Park, New York, 11042, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.